【Hocance Biotech】Announcement of the Company's Q1 2026 Consolidated Financial Report Submitted to the Board of Directors
NQ Score
0/100
N1 Content Completeness
80
AI Summary (NQ-processed)
Hocance Biotech submitted its Q1 2026 consolidated financial report to the board. For the period from January 1 to March 31, 2026, operating revenue was NT$190,868 thousand, net profit attributable to parent company owners was NT$52,793 thousand, and basic EPS was NT$0.59.